实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (3): 430-433.doi: 10.3969/j.issn.1672-5069.2025.03.028

• 肝癌 • 上一篇    下一篇

15例肝细胞癌发生消化道穿孔患者临床特征分析*

刘松涛, 李娟, 刘梅, 刘晖, 闾军   

  1. 100069 北京市 首都医科大学附属北京佑安医院肿瘤内科(刘松涛,李娟,刘梅,闾军);病理科(刘晖)
  • 收稿日期:2024-09-14 发布日期:2025-05-14
  • 通讯作者: 闾军,E-mail:lujun98@ccmu.edu.cn
  • 作者简介:刘松涛,男,43岁,医学博士,副主任医师。E-mail: botao8080@163.com
  • 基金资助:
    *国家重点研发计划“前沿生物技术”重点专项项目(编号:2022YFC3401400);国家重点研发计划“合成生物学”重点专项项目(编号:2022YFA0912400);北京市医院管理中心“登峰”人才培养计划项目(编号:DFL20221502);北京佑安医院中青年人才联合攻关项目(编号:BJYAYY-GG2019-01)

Clinical feature of gastrointestinal perforation in patients with hepatocellular carcinoma: Analysis of 15 cases

Liu Songtao, Li Juan, Liu Mei, et al   

  1. Department of Medical Oncology, You’An Hospital, Capital Medical University, Beijing 100069, China
  • Received:2024-09-14 Published:2025-05-14

摘要: 目的 总结肝细胞癌(HCC)患者发生消化道穿孔的临床特点,以借鉴处理经验。方法 2017年1月~2024年7月我院诊治的HCC患者发生消化道穿孔15例,给予对症、手术或肝移植处理,观察预后。结果 在15例HCC并发消化道穿孔患者中,男11例,女4例,平均年龄为59.4 ± 9.8岁;其中慢性乙型肝炎12例,酒精性肝病1例,不明原因肝病2例;15例患者均有腹痛,中位持续时间为2(1,10)d;外周血WBC计数为(8.3±4.9×109/L),中性粒细胞百分比为(82.5±9.8%),ALB为(29.3±5.6 g/L),PTA为(59.5±10.3%);发生穿孔的部位为胃部、十二指肠、空肠、回肠和结肠,分别为6例(40.0%)、2例(13.3%)、1例(6.7%)、2例(13.3%)和4例(26.7%);3例接受内科对症,半月内死亡,12例行手术修补治疗,3例死亡,9例治愈;在9例生存患者中,2例行肝移植治疗,4例接受肝动脉栓塞术和/或靶向药物治疗,2例接受内科对症治疗,1例肿瘤无复发而定期监测,结果7例死亡,2例生存,平均生存时间为(22.2±19.3)个月。结论 HCC患者在有创性和系统药物治疗过程中,有发生消化道穿孔的风险。一旦发生,需积极手术治疗。在穿孔治愈后可继续应用靶向药物等治疗肿瘤。

关键词: 肝细胞癌, 消化道穿孔, 临床特点, 治疗

Abstract: Objective The aim of this study was to summarize clinical feature of gastrointestinal perforation (GIP) in patients with hepatocellular carcinoma (hcc). Methods 15 patients with GIP and underlying HCC were encountered in our hospital between January 2017 and July 2024, and all patients were carefully dealt with conventionally or surgically. Results Of the 15 patients with GIP and HCC, 11 were male and 4 female, with average age of (9.4±9.8) year old; 12 patients were infected with hepatitis B virus, 1 had alcoholic liver disease and 2 were cryptogenic; all the 15 patients had abdominal pain with a median duration of 2 d(1 hour,10 d); blood WBC count was (8.3±4.9×109/L) with neutrophil percentage of(82.5±9.8%), serum albumin level was (29.3±5.6 g/L), and prothrombin time activity was (59.5±10.3%); the perforated sites in stomach, duodenum, jejunum, ileum and colon were 6 cases (40.0%), 2 cases (13.3%), 1 case (6.7%), 2 cases (13.3%) and 4 cases (26.7%), respectively; three patients died after supporting treatment, with an average survival of 15 days, the remaining 12 patients underwent surgical repairment, with 3 died and 9 survived; of the 9 survivals, 2 underwent liver transplantation, 4 underwent hepatic artery embolization and/or targeted and/or immune therapy, 2 underwent internal supporting treatment and 1 had regular monitoring, the outcomes were 7 died and 2 survived, with mean survival time of (22.2±19.3) months. Conclusion The patients with HCC have the risk of GIP during invasive and systemic treatment, and an appropriate surgical repairment should be done in time once it occur.

Key words: Hepatocellular carcinoma, Gastrointestinal perforation, Clinical feature, Treatment